Case | HBS Case Collection | 2007 (Revised from original 2006 version)
by Richard G. Hamermesh and Brian DeLacey
Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company.
Keywords: Private Equity; Initial Public Offering; Leveraged Buyouts; Mergers and Acquisitions; Health Care and Treatment; Pharmaceutical Industry; United States;
Citation:
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (A): From LBO to...?" Harvard Business School Case 806-064, May 2007. (Revised from original January 2006 version.)
View Profile »View Publications »
Course Overview Note | 2013 (Revised from original 2013 version)
The Entrepreneurial Manager: Course Overview, 2013 Winter Term
Richard G. Hamermesh, Richard G. Hamermesh and Thomas Eisenmann
Keywords: Entrepreneurship; Management; Business Education;
Case | HBS Case Collection | 2013 (Revised from original 2012 version)
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Richard G. Hamermesh, Norman C. Selby and Phillip Andrews
Keywords: models of reimbursement; personalized medicine; regulation; healthcare reform; Health Care and Treatment; Health Industry; United States;
Case | HBS Case Collection | 2012 (Revised from original 2011 version)
eHealthpoint: Healthcare for Rural India
Richard G. Hamermesh, Mona Sinha and Elizabeth Vrolyk
Keywords: Health Care and Treatment; Health Industry; India;